SB 793 makes targeted changes to Maryland law governing opioid overdose reversal drugs, including naloxone and other FDA-approved products used to reverse overdoses. The bill requires a licensed health care provider issuing a standing order to allow an individual to choose any formulation of any FDA-approved opioid overdose reversal drug, rather than limiting the person to a particular product or dosage form. It also clarifies that pharmacists may dispense these drugs under existing therapy management arrangements.
The bill further adds a new provision stating that an authorized private or public entity that prescribes and dispenses opioid overdose reversal drugs cannot be required to keep in stock or dispense every FDA-approved formulation. In practical terms, this protects clinics, local health departments, community organizations, and similar entities from an obligation to stock the full range of products while still allowing them to provide overdose reversal medication under standing orders and written agreements. The bill takes effect October 1, 2025.
Impact
SB 793 amends Title 13, Subtitle 31 of the Health – General Article, specifically the state’s opioid overdose reversal drug framework. It changes the standing-order process in § 13-3106 to require patient choice among FDA-approved formulations and adds new § 13-3110 to limit stocking and dispensing obligations for authorized private or public entities. The bill affects licensed health care providers, pharmacists, local health departments, community-based organizations, substance use treatment organizations, and other entities involved in overdose prevention and distribution.
Sentiment
Based on the bill text and the absence of recorded committee testimony or votes in the provided materials, the overall tone appears practical and administrative rather than controversial. The measure seems aimed at improving access and flexibility for overdose reversal drugs while reducing operational burdens on providers and community entities. No formal opposition or support is documented in the supplied context.
Contention
The main policy tension is between expanding individual choice in overdose reversal drug formulations and avoiding mandates that entities stock every FDA-approved product. Supporters would likely emphasize access, flexibility, and patient preference, while potential critics could question whether allowing entities not to stock all formulations might limit availability in some settings. No specific objections, amendments, or named stakeholders are included in the provided committee or voting history.